Apomorphine-induced eosinophilic panniculitis and hypereosinophilia in Parkinson disease.
Pot
C
C
Neurology Department, Geneva University Hospitals and Medical School, Switzerland.
Oppliger
R
R
Castillo
V
V
Coeytaux
A
A
Hauser
C
C
Burkhard
P R
PR
D000978:Antiparkinson Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001058:Apomorphine / Q000009:adverse effects* / Q000627:therapeutic use; D018491:Dopamine Agonists / Q000009:adverse effects* / Q000627:therapeutic use; D003875:Drug Eruptions / Q000209:etiology*; D005260:Female; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000139:chemically induced*; D008875:Middle Aged; D015434:Panniculitis / Q000139:chemically induced*; D010300:Parkinson Disease / Q000150:complications* / Q000188:drug therapy
D000978:Antiparkinson Agents; D018491:Dopamine Agonists; D001058:Apomorphine